AI, Robotics, and the New Era of Pharma Production
Pharmaceuticals and biotech remain two of the most active sectors for global capital investment heading into 2025. From explosive growth in GLP-1 weight-loss drug production to the expansion of biologics and cell & gene therapies, the project pipeline is strong—but not without challenges.
In this episode of Navigating the Currents of Change, Shaheen Chohan is joined by Annette Kreuger, IIR’s Senior Vice President of Research for Pharma & Biotech, to explore:
Whether you're tracking investment trends, project pipelines, or the future of pharmaceutical infrastructure—this episode delivers the data-backed insight you need.
In this episode of Navigating the Currents of Change, Shaheen Chohan is joined by Annette Kreuger, IIR’s Senior Vice President of Research for Pharma & Biotech, to explore:
- What’s driving CAPEX in pharma and biotech heading into 2025
- Where reshoring and “campus-style” mega facilities are being planned
- How CDMOs and CMOs like Lonza and Thermo Fisher are fueling growth
- The role of smart manufacturing, AI, and automation in project development
- How global trade policies and tariffs are impacting the project landscape
Whether you're tracking investment trends, project pipelines, or the future of pharmaceutical infrastructure—this episode delivers the data-backed insight you need.
